In addition, two of three patients with relapsed/refractory BPDCN sustained two additional durable CRs following a single cycle of SL-401. With these CRs, malignant blasts were no longer detectable in the bone marrow and blood. In addition, in one CR, there was also normalization of hepatic and splenic enlargement, and in the other CR there was resolution of associated malignant skin lesions. SL-401 was well-tolerated at clinically active doses, and had no evidence of treatment-related bone marrow suppression.
In a second study, another agent being developed by Stemline, SL-101, demonstrated preclinical efficacy against lymphoid cancers including Hodgkin's lymphoma. SL-101 is a novel monoclonal antibody-conjugate that targets CD123 with high affinity. SL-101 demonstrated preclinical anti-cancer activity against several Hodgkin's lymphoma cell lines, as well as anti-cancer activity against mantle cell lymphoma and T-cell acute lymphoid leukemia. The results of this study warrant further evaluation of SL-101 in lymphoid cancers including Hodgkin's lymphoma.
Details on the abstracts selected for presentation are as follows:
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
Abstract #: 3625
Lead Author: Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center
Session: 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster III
Date/Time: Monday, December 10, 2012; 6:00 – 8:00pm ET
Location: Hall B1-B2 (Georgia World Congress Center)
SL-101, a Novel Monoclonal Antibody-Conjugate That Targets Interleukin-3 Receptor Alpha (CD123), Possesses Preclinical Anti-Tumor Activity Against Hodgkin's Lymphoma
|SOURCE Stemline Therapeutics, Inc|
Copyright©2012 PR Newswire.
All rights reserved